Korea University College of Medicine is set to lead a government-supported hantavirus vaccine initiative centered on self-amplifying mRNA (sa-mRNA) and a next-generation lipid nanoparticle (LNP) delivery system. The program will run through the institution’s Vaccine Innovation Center. The effort targets hantavirus infection, which can cause hantavirus pulmonary syndrome (HPS) or hemorrhagic fever with renal syndrome (HFRS) depending on viral strain. The work aims to generate next-generation vaccine candidates using sa-mRNA to enable RNA replication in cells and support immune responses at lower dose levels than conventional mRNA platforms. Korea University said it will leverage two domestically developed technologies and aims to reduce dependence on overseas intellectual property, while supporting rapid vaccine development and manufacturing. The initiative reflects renewed attention to preparedness for emerging and re-emerging infectious diseases, extending mRNA platform investments beyond COVID-19 into additional viral threats.